Sera Prognostics Q4 revenue falls, net loss narrows
Overview
Pregnancy diagnostics company's Q4 revenue fell yr/yr
Net loss for Q4 narrowed compared to prior-year period
Outlook
Company expects cash position to fund operations through significant milestones into 2028
Result Drivers
COMMERCIAL INVESTMENT - Co said it continued targeted commercial activities and strategic headcount additions in Q4 while building market awareness in preparation for PRIME study publication
R&D SPENDING - Research and development expenses were stable in Q4, with full-year decline attributed to lower clinical study costs after completion of the PRIME study
Company press release: ID:nPnbhhS0Sa
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Miss | $10,000 | $30,000 (2 Analysts) |
Q4 Net Income |
| -$7.9 mln |
|
Q4 Basic EPS |
| -$0.16 |
|
Q4 Income from Operations |
| -$8.95 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the business support services peer group is "buy."
Wall Street's median 12-month price target for Sera Prognostics Inc is $5.00, about 148.8% above its March 17 closing price of $2.01
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
